Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Nebula

- PMLiVE

Merck KGaA given FDA Fast Track designation for generalised myasthenia gravis drug

Cladribine capsules could become the first ever oral treatment for gMG

- PMLiVE

Merck KGaA expands rare tumour portfolio with $3.9bn SpringWorks acquisition

SpringWorks’ Gomekli was approved by the FDA earlier this year to treat patients with NF1

- PMLiVE

Merck KGaA’s Mavenclad tablets recommended by NICE for wider MS use

The neurological disorder affects more than 150,000 people in the UK

- PMLiVE

Merck KGaA/Abbisko share positive phase 3 results for pimicotinib in rare tumour type

The companies entered into a licensing agreement for the candidate in December last year

- PMLiVE

Vertex and Genomics expand collaboration to accelerate precision medicines

The partners have been working together since 2018 to develop treatments for serious diseases

- PMLiVE

Merck KGaA signs definitive agreement to acquire Mirus Bio in deal worth $600m

The deal aims to advance Merck’s viral vector manufacturing of cell and gene therapies

- PMLiVE

Merck KGaA and Caris enter oncology partnership worth over $1.4bn

The alliance is aimed at accelerating the development of ADCs for cancer patients

- PMLiVE

Merck KGaA and C4 Therapeutics enter protein degrader partnership worth $756m

The collaboration will utilise C4T’s TORPEDO platform to target and degrade disease-associated proteins

- PMLiVE

UKHSA publishes five-year strategy to detect risk-posing pathogens in UK

The strategy will help to improve the UK's response to infectious disease threats

- PMLiVE

Merck gains rights to Inspirna’s colorectal cancer drug for $45m upfront

Ompenaclid is in phase 2 development to treat advanced or metastatic colorectal cancer

- PMLiVE

Merck gains rights to Abbisko’s pimicotinib in deal worth over $70m

The candidate is currently in late-stage development for tenosynovial giant cell tumour

- PMLiVE

New study finds dose of subcutaneous cladribine could predict MS relapse risk

The disease affects approximately 130,000 people in the UK and currently has no cure

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links